Benzinga | Aug 10, 2020 04:20PM EDT

Castle Biosciences Q2 EPS $(0.08) Beats $(0.40) Estimate, Sales $12.70M Up From $10.74M YoY

Castle Biosciences (NASDAQ:CSTL) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.40) by 80 percent. This is a 92.38 percent increase over losses of $(1.05) per share from the same period last year. The company reported $12.70 million in sales this quarter. This is a 18.26 percent increase over sales of $10.74 million the same period last year.